Novo Nordisk A/S
Pagina dedicata companiei Novo Nordisk A/S listata cu simbolul US.NVO
Descriere companieModificare
Novo Nordisk A/S (https://www.novonordisk.com/) is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Grafic actiuni companieModificare
Ultimele stiri despre Novo Nordisk A/S (US.NVO)Modificare
- Turismul in Romania - 06 februarie 2025
- Topul administratorilor de fonduri mutuale in 2024 - 29 ianuarie 2025
- Impactul downgrade-ului pe bursa - 28 ianuarie 2025
- Pilonul II primeste un boost - 26 decembrie 2024
- Industria romaneasca, in crestere - 18 decembrie 2024
- Pilonul II, afectat de scaderea bursei - 05 decembrie 2024
- Cum reactioneaza BVB-ul? - 07 noiembrie 2024
- Constructiile rezidentiale in scadere - 25 septembrie 2024
- Novo Nordisk A/S
- BNR reduce dobanda de referinta - 08 august 2024